Premium
Immunohistochemical study of bone GLA protein in primary bone tumors
Author(s) -
Lwasaki Renpei,
Yamamuro Takao,
Kotoura Yoshihiko,
Okumura Hideo,
Kasai Ryuichi,
Nakashima Yasuaki
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920801)70:3<619::aid-cncr2820700313>3.0.co;2-5
Subject(s) - osteosarcoma , chondrosarcoma , immunohistochemistry , giant cell , pathology , medicine , osteoid , giant cell tumor of bone , differential diagnosis , giant cell tumors , grading (engineering) , biology , ecology
Methods. The immunoreactivity of bone GLA protein (BGP) in primary bone tumors, including osteosarcoma, chondrosarcoma, malignant fibrous histiocytoma of bone (MFH), and giant cell tumor of bone (GCT), was investigated with anti‐BGP rabbit serum and peroxidase‐antiperoxidase complex. Results. As to intracellular localization, BGP antigenicity was detected in 33 of 35 cases of osteosarcoma and 12 of 25 cases of chondrosarcoma. However, there were no positive findings in all 15 cases of MFH or 20 cases of GCT. In chondrosarcoma, the frequency of positively stained cases increased according to pathologic grading (i.e., 3 of 14 cases of Grade 1, 7 of 9 cases of Grade 2, and 2 of 2 cases of Grade 3). Although the multinucleated cells in MFH or GCT were not immunostained, BGP antigenicity was observed in the multinucleated cells of osteosarcoma (12 of 15 cases). In the matrix of osteosarcoma, BGP immunoreactivity of the tumorous osteoid was observed in 28 of 32 cases. However, in the matrices of chondrosarcoma, MFH, and GCT, BGP immunoreactivity was not observed. Conclusion. These results suggest that the immunohistochemical study of BGP is useful for the differential diagnosis of bone tumors. Cancer 1992; 70:619–624.